SCHEMBL383913

SCHEMBL383913

Cn1c2ccccc2c(=O)c2c(-c3ccccc3NC(=O)C(C)(C)C)cccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.56
MAPT P10636 3/20 0.56
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 6/20 0.44
HSD17B10 Q99714 3/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 2/20 0.42
CETP P11597 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
KDM1A O60341 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPY5R Q15761 1/20 0.40
NPC1 O15118 1/20 0.40
USP2 O75604 1/20 0.40
RAB9A P51151 1/20 0.40
NTRK1 P04629 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2087952 0.75 CETP (0.67) MAPTALDH1A1KDM4ELMNATSHR
SCHEMBL10168172 0.73 MAPT (0.59) HTTMAPTALDH1A1KDM4EHSD17B10
SCHEMBL9352178 0.72 HTT (1.00) HTTMAPTALDH1A1KDM4EHSD17B10
SCHEMBL16376471 0.72 GPR3 (0.62) HTTMAPTALDH1A1KDM4EHSD17B10
SCHEMBL12284944 0.70 CETP (0.59) ALDH1A1KDM4ELMNATSHRCETP
SCHEMBL27653133 0.70 MAPT (0.61) HTTMAPTALDH1A1KDM4EHSD17B10
Adosopine SCHEMBL2109279 0.69 MAPT (0.50) HTTMAPTALDH1A1KDM4EHSD17B10
SCHEMBL10812522 0.69 RXFP1 (0.52) HTTMAPTALDH1A1KDM4ELMNA
SCHEMBL4728699 0.69 NPY5R (0.78) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL5706504 0.68 CETP (0.71) ALDH1A1KDM4ELMNATSHRCETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1330456-B8 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-02-08 EP disclosed
EP-1330456-B9 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-01-25 EP disclosed
EP-1330456-B1 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2011-06-15 EP disclosed
US-7115619-B2 N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-10-03 US disclosed
US-20040063739-A1 N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2004-04-01 US disclosed
EP-1330456-A2 N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2003-07-30 EP disclosed
WO-2002030932-A2 N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063739-A1 N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents TERT, MKI67, NQO2 HTT 1530/4885MAPT 2342/4885ALDH1A1 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.